• Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1 GLOBE NEWSWIRE (May 19, 2026)
  
  
• Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook GLOBE NEWSWIRE (Jan 08, 2026)
  
  
• Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months GLOBE NEWSWIRE (Dec 23, 2025)
  
  
• Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook Businesswire (Sep 04, 2025)
  
  
• Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference Businesswire (Sep 03, 2025)
  
  
• Bone Biologics Announces Closing of $5.0 Million Public Offering Businesswire (Jun 30, 2025)
  
  
• Bone Biologics Announces Pricing of $5.0 Million Public Offering Businesswire (Jun 27, 2025)
  
  
• Bone Biologics Files Patent Application for Bone Regeneration Technology Businesswire (Jun 27, 2025)
  
  
• Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements Businesswire (Jun 26, 2025)
  
  
• Bone Biologics Announces 1-for-6 Reverse Stock Split Businesswire (Jun 06, 2025)
  
  
• Bone Biologics Appoints Phillip T. Meikle to its Board of Directors Businesswire (Oct 21, 2024)
  
  
• Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference Businesswire (Sep 04, 2024)
  
  
• Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds Businesswire (Aug 02, 2024)
  
  
• First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion Businesswire (Jun 20, 2024)
  
  
• Bone Biologics Announces Closing of $2.0 Million Public Offering Businesswire (Mar 06, 2024)
  
  
• Bone Biologics Announces Pricing of $2.0 Million Public Offering Businesswire (Mar 04, 2024)
  
  
• Bone Biologics Reports Progress With NB1 Clinical Program Businesswire (Mar 01, 2024)
  
  
• Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors Businesswire (Jan 11, 2024)
  
  
• Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements Businesswire (Jan 10, 2024)
  
  
• Bone Biologics Announces 1-for-8 Reverse Stock Split Businesswire (Dec 18, 2023)
  
  
• Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Businesswire (Nov 20, 2023)
  
  
• Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Businesswire (Nov 16, 2023)
  
  
• Bone Biologics Provides Scientific Update on NB1 Bone Graft Device Businesswire (Sep 26, 2023)
  
  
• Bone Biologics Prices $5.0 Million Underwritten Public Offering Businesswire (Jun 14, 2023)
  
  
• Bone Biologics Effects 1-for-30 Reverse Stock Split Businesswire (Jun 06, 2023)
  
  
• Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia Businesswire (Apr 11, 2023)
  
  
• Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization Businesswire (Jan 26, 2023)
  
  
• Bone Biologics CEO Issues Letter to Stockholders Businesswire (Oct 25, 2022)
  
  
• Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering Businesswire (Oct 12, 2022)
  
  
• CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering Businesswire (Oct 07, 2022)
  
  
• Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest Businesswire (Mar 23, 2022)
  
  
• Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix Businesswire (Mar 07, 2022)
  
  
• Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference Businesswire (Jan 05, 2022)
  
  
• Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq Businesswire (Oct 18, 2021)
  
  
• Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split Businesswire (Oct 13, 2021)
  
  
• Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation Businesswire (Jan 07, 2020)
  
  
• Bone Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX®) in Australia Businesswire (Mar 25, 2019)
  
  
• Bone Biologics Completes $5.9 Million of Financing Businesswire (Jul 23, 2018)
  
  
• Bone Biologics Completes $500,000 of Financing Businesswire (Mar 29, 2018)
  
  
• Bone Biologics Release: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties Businesswire (Dec 20, 2017)
  
  
• Bone Biologics Adds Osteoporosis and Trauma Indications to its Portfolio Businesswire (Aug 23, 2017)
  
  
• Bone Biologics Completes $1.4 Million Round of Financing Businesswire (Aug 22, 2017)
  
  
• Bone Biologics Announces Appointment of Bret Hankey to Company's Board of Directors Businesswire (Aug 03, 2017)
  
  
• Bone Biologics Corporation Announces Commencement of a Private Placement of Securities Businesswire (Jul 24, 2017)
  
  
• Bone Biologics Names Scott D. Boden, MD Chief Medical Advisor Businesswire (Jul 06, 2016)
  
  
• Bone Biologics Announces Signing of Option to License Revolutionary Bone Growth Factor Nell-1 from UCLA for Use in Osteoporosis Businesswire (Jun 14, 2016)
  
  
• Bone Biologics Completes $5.75 Million Round Of Financing PRNewswire (Feb 29, 2016)